Lipe & Dalton’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $119K | Hold |
4,954
| – | – | 0.06% | 80 |
|
|
2026
Q1 | $139K | Hold |
4,954
| – | – | 0.07% | 76 |
|
|
2025
Q4 | $123K | Buy |
4,954
+2,295
| +86% | +$57.9K | 0.06% | 80 |
|
|
2025
Q3 | $68K | Hold |
2,659
| – | – | 0.03% | 85 |
|
|
2025
Q2 | $64K | Hold |
2,659
| – | – | 0.03% | 83 |
|
|
2025
Q1 | $67K | Hold |
2,659
| – | – | 0.04% | 83 |
|
|
2024
Q4 | $71K | Buy |
2,659
+400
| +18% | +$10.8K | 0.04% | 86 |
|
|
2024
Q3 | $65K | Hold |
2,259
| – | – | 0.03% | 94 |
|
|
2024
Q2 | $63K | Sell |
2,259
-500
| -18% | -$13.8K | 0.03% | 92 |
|
|
2024
Q1 | $77K | Hold |
2,759
| – | – | 0.04% | 95 |
|
|
2023
Q4 | $79K | Hold |
2,759
| – | – | 0.04% | 92 |
|
|
2023
Q3 | $92K | Hold |
2,759
| – | – | 0.06% | 88 |
|
|
2023
Q2 | $101K | Hold |
2,759
| – | – | 0.06% | 88 |
|
|
2023
Q1 | $113K | Hold |
2,759
| – | – | 0.06% | 84 |
|
|
2022
Q4 | $141K | Hold |
2,759
| – | – | 0.08% | 81 |
|
|
2022
Q3 | $121K | Hold |
2,759
| – | – | 0.08% | 83 |
|
|
2022
Q2 | $145K | Hold |
2,759
| – | – | 0.08% | 83 |
|
|
2022
Q1 | $143K | Sell |
2,759
-80
| -3% | -$4.15K | 0.07% | 84 |
|
|
2021
Q4 | $168K | Hold |
2,839
| – | – | 0.08% | 82 |
|
|
2021
Q3 | $122K | Hold |
2,839
| – | – | 0.06% | 83 |
|
|
2021
Q2 | $111K | Hold |
2,839
| – | – | 0.06% | 87 |
|
|
2021
Q1 | $103K | Sell |
2,839
-1
| -0% | -$36 | 0.06% | 83 |
|
|
2020
Q4 | $105K | Sell |
2,840
-395
| -12% | -$14.5K | 0.06% | 80 |
|
|
2020
Q3 | $113K | Hold |
3,235
| – | – | 0.08% | 79 |
|
|
2020
Q2 | $100K | Hold |
3,235
| – | – | 0.07% | 82 |
|
|
2020
Q1 | $100K | Sell |
3,235
-474
| -13% | -$16.2K | 0.08% | 76 |
|
|
2019
Q4 | $138K | Hold |
3,709
| – | – | 0.09% | 79 |
|
|
2019
Q3 | $126K | Hold |
3,709
| – | – | 0.09% | 78 |
|
|
2019
Q2 | $152K | Sell |
3,709
-1,054
| -22% | -$41.9K | 0.11% | 71 |
|
|
2019
Q1 | $192K | Hold |
4,763
| – | – | 0.14% | 66 |
|
|
2018
Q4 | $197K | Buy |
4,763
+1,054
| +28% | +$43.8K | 0.16% | 62 |
|
|
2018
Q3 | $155K | Hold |
3,709
| – | – | 0.11% | 65 |
|
|
2018
Q2 | $128K | Buy |
3,709
+158
| +4% | +$5.4K | 0.09% | 67 |
|
|
2018
Q1 | $120K | Buy |
3,551
+84
| +2% | +$2.89K | 0.09% | 72 |
|
|
2017
Q4 | $119K | Sell |
3,467
-1,409
| -29% | -$48K | 0.08% | 68 |
|
|
2017
Q3 | $165K | Hold |
4,876
| – | – | 0.12% | 62 |
|
|
2017
Q2 | $155K | Buy |
4,876
+316
| +7% | +$9.96K | 0.1% | 68 |
|
|
2017
Q1 | $148K | Buy |
4,560
+1
| +0% | +$32 | 0.11% | 66 |
|
|
2016
Q4 | $141K | Buy |
+4,559
| New | +$139K | 0.1% | 66 |
|
|
2016
Q3 | – | Sell |
-4,559
| Closed | -$152K | – | 89 |
|
|
2016
Q2 | $152K | Buy |
+4,559
| New | +$146K | 0.1% | 93 |
|
Other funds holding PFE
AIM
SLAM
CWP
Lipe & Dalton's PFE Position: Q2 2026 in Review
Lipe & Dalton held its Pfizer (PFE) position steady in Q2 2026 at 4,954 shares worth $119K. The position accounts for 0.06% of the portfolio, ranked #80.
Lipe & Dalton first reported a position in PFE in Q2 2016 and has held it in 40 quarters since. The position peaked at $197K in Q4 2018. 1,338 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Lipe & Dalton held 4,954 shares of Pfizer worth $119K as of Q2 2026.
- Lipe & Dalton left its Pfizer share count unchanged in Q2 2026.
- Pfizer made up 0.06% of Lipe & Dalton's portfolio in Q2 2026, its #80 holding.
- Lipe & Dalton first reported a position in Pfizer in Q2 2016 and has held it in 40 quarters since.
- Lipe & Dalton's Pfizer position peaked at $197K in Q4 2018.
- 1,338 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Lipe & Dalton's 13F filing for Q2 2026, filed 14 Jul 2026.